Technical Analysis for EFTR - eFFECTOR Therapeutics, Inc.

Grade Last Price % Change Price Change
F 0.00 0.00% 0.00
EFTR closed unchanged on Tuesday, November 19, 2024, on 30 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

eFFECTOR Therapeutics, Inc. Description

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Cancer Treatment Molecular Biology Breast Cancer Antineoplastic Drugs Lung Cancer Signal Transduction NSCLC Non Small Cell Lung Carcinoma Pembrolizumab Kinase 1

Is EFTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.13
52 Week Low 0.0002
Average Volume 692,862
200-Day Moving Average 8.13
50-Day Moving Average 0.81
20-Day Moving Average 0.05
10-Day Moving Average 0.00
Average True Range 0.05
RSI (14) 14.53
ADX 64.5
+DI 9.44
-DI 49.70
Chandelier Exit (Long, 3 ATRs) 0.17
Chandelier Exit (Short, 3 ATRs) 0.16
Upper Bollinger Bands 0.18
Lower Bollinger Band -0.09
Percent B (%b) 0.33
BandWidth 585.84
MACD Line -0.24
MACD Signal Line -0.31
MACD Histogram 0.0639
Fundamentals Value
Market Cap 683.33
Num Shares 3.42 Million
EPS -18.75
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 54.16
Price-to-Book 13.38
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.00
Resistance 3 (R3) 0.00 0.00 0.00
Resistance 2 (R2) 0.00 0.00 0.00 0.00
Resistance 1 (R1) 0.00 0.00 0.00 0.00 0.00
Pivot Point 0.00 0.00 0.00 0.00 0.00
Support 1 (S1) 0.00 0.00 0.00 0.00 0.00
Support 2 (S2) 0.00 0.00 0.00 0.00
Support 3 (S3) 0.00 0.00 0.00
Support 4 (S4) 0.00